Selinexor plus R-CHOP for first-line treatment of TP53-mutated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with DLBCL that has a TP53 gene mutation.
- You have not received any prior chemotherapy for lymphoma (previous localized radiation is okay).
- You have at least one tumor that can be measured on scans.
- You are in reasonably good health (able to care for yourself, adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding selinexor to a standard chemotherapy regimen (BEAM) before a stem cell transplant for people with a certain type of large B-cell lymphoma that has MYC positive. It aims to see if this combination can improve outcomes.
This Phase 2 trial studies selinexor added to standard R-CHOP chemotherapy in people with a high-risk type of diffuse large B-cell lymphoma (DLBCL) that is “germinal center B-cell” (GC). It aims to improve disease control in people who need stronger treatment at the start.
This trial tests a new combination: selinexor (a pill that targets cancer cells) plus a standard chemotherapy regimen (R-GDP) for people with relapsed or refractory DLBCL that has a specific genetic change in the TP53 gene. The goal is to see if this combination can help when other treatments have stopped working.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a combination of three drugs (selinisole, azacitidine, and venetoclax) for newly diagnosed blood cancers that have mutations in a gene called TP53. These mutations make the cancer harder to treat, and this study aims to see if combining these medications can help control the disease better.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.